Cytogen to license prostate test technology:
This article was originally published in Clinica
Executive Summary
Cytogen plans to obtain an exclusive, worldwide licence to Molecular Staging's Rolling Circle Amplification Technology (RCAT) to develop in vitro tests for prostate specific membrane antigen (PSMA) and prostate specific antigen (PSA). According to Princeton, New Jersey-based Cytogen, serum PSMA is increased in prostate cancer, but appears to be unaffected by other miscellaneous events, unlike PSA. Cytogen plans to use the RCAT technology to develop a PSMA and PSA test for prostate cancer and hopes to have an assay for clinical study by mid-2000.
You may also be interested in...
EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
Hair Supplement Linked To Cases Of Severe Hepatitis In France
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: